IPP Bureau
Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications
By IPP Bureau - July 23, 2025
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Lonza reports 19% growth in sales in H1
By IPP Bureau - July 23, 2025
Upgrades 2025 full-year CDMO sales and margin outlook
Torrent Pharma launches nutrition supplement powder Shelcal Total
By IPP Bureau - July 23, 2025
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Fortis and Gleneagles India deepen collaboration to drive growth
By IPP Bureau - July 23, 2025
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
By IPP Bureau - July 23, 2025
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
AstraZeneca plans to invest $50 billion in US by 2030
By IPP Bureau - July 22, 2025
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
By IPP Bureau - July 21, 2025
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Sarepta refuses to comply with FDA request to stop shipping gene therapy Elevidys
By IPP Bureau - July 21, 2025
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Miltenyi Biotec and THSTI partner to launch CAR-T Cell and gene therapy training curriculum
By IPP Bureau - July 21, 2025
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Roche provides update on astegolimab in chronic obstructive pulmonary disease
By IPP Bureau - July 21, 2025
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint
By IPP Bureau - July 21, 2025
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
By IPP Bureau - July 21, 2025
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer
By IPP Bureau - July 21, 2025
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
ImCheck’s ICT01 receives FDA ODD for treatment of acute myeloid leukemia
By IPP Bureau - July 21, 2025
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Neuberg Pulse partners with Dhoni to launch diagnostics centre in Ranchi
By IPP Bureau - July 21, 2025
Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years
